https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-21 16:19:122021-10-21 16:19:12Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-21 08:06:542021-10-21 08:06:54ONA Therapeutics Strengthens Scientific Leadership Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-20 14:37:032021-10-20 14:37:03Novo Holdings Leads US$21M Series A Financing in BI-OMILQ
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-19 16:03:582021-10-19 16:03:58LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-19 15:59:502021-10-19 15:59:50Pyxis Announces Pricing of Upsized Initial Public Offering
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-18 11:40:572021-10-18 11:40:57Arix Bioscience plc Business Update and Cancellation of Share Buyback
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-18 08:58:232021-10-18 08:58:23Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-14 13:22:502021-10-14 13:22:50Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-08 07:03:462021-10-08 07:03:46Futura Medical plc Board Appointment
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-07 09:11:182021-10-07 09:11:18MinervaX provides clinical and leadership update
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-07 06:15:392021-10-07 06:15:39HEALTHCAP STRENGTHENS SENIOR TEAM
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-06 08:56:422021-10-06 08:56:42Arix today announces the following updates to its Board and Executive team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-05 17:02:202021-10-05 17:02:20Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-05 12:18:082021-10-05 12:18:08Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-04 14:01:542021-10-04 14:01:54DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-04 13:59:422021-10-04 13:59:42ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-04 11:06:062021-10-04 11:06:06Versameb at Sachs 21st Annual Biotech in Europe Forum
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-10-01 13:30:212023-06-14 15:53:01Optimum Strategic Communications Hosts 13th Annual Healthcare Investor Conference
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-08-12 10:57:142023-06-14 15:53:23Arix Bioscience plc Interim results for the six months ended 30 June 2021
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2021-06-30 18:35:062023-06-14 15:53:36Optimum Strategic Communications Expands Team to support ongoing growthFor more information about Optimum Strategic Communications, please get in touch.
